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Abstract 
The VR1012NH36 DNA vaccine was immunoprophylactic and immunotherapeutic against mice visceral leishmaniasis by 
L.(L.) chagasi and cutaneous leishmaniasis by L. (L.) mexicana. We here evaluated the protection induced by three sc doses of 
FML (150µg) + saponin (100µg), or two doses of VR1012 empty plasmid (100µg) or VR1012NH36 (100µg) vaccine against the 
footpad L. (L.) amazonensis infection with 1 million promastigotes. After infection, the anti-FML IgG, IgG1 and IgG2a 
antibodies were significantly increased over the saline controls only in the FML saponin vaccinated animals. The DTH response 
against L.(L.) amazonesis lysate was increased by both vaccines over the saline controls before infection. Regarding the reduction 
of parasite lesions, at week 26 after infection, significant differences were found in the footpad swelling (ANOVA; p=0.004). 
Protection was measured as the reduction in footpad swelling. Considering the mean values of each group as well as the 
individual results, the highest protection was determined by the DNA vaccine followed by the FML saponin vaccine. The DNA 
vaccine induced 80.4%, the empty plasmid 26.5% and the FML vaccine, 49% of reduction (p<0.05) indicating antigen-specific 
protection. Indeed, the increase in footpad sizes was detected in 5 of 7 mice treated with saline, 3 treated with empty plasmid, in 
1 treated with the FML and in only 2 treated with the NH36 DNA vaccine. Noteworthy, the increase in the NH36 DNA treated 
mice started on week 26 while in other groups, between weeks 12-14. At the end of the assay, on week 33, survival was 90% for 
the DNA vaccine group and 70% for the empty plasmid, FMLSAP and saline treated animals. Of note, while deaths begun at 
week 12 in other groups, the only obit in the DNA vaccinated animals occurred at week 33. Our results point out that the NH36 
gene of L. (L.) donovani, as a DNA vaccine, followed by the FMLSAP vaccine, induce significant cross-protective response 
against tegumentar leishmaniasis induced by L.(L.) amazonensis, indicating its potential use as a bivalent vaccine against visceral 
and tegumentar leishmaniasis.  
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NH36, an important phylogenetic marker of the Leishmania genus [1] is a nucleoside hydrolase of 34.3 kDA that 
cleaves nucleosides from imported nucleic acids to release free purine or pyrimidic bases for Leishmania replication. 
It is also the main antigenic marker of the FML complex of Leishmania donovani [2] which, together with Quillaja 
saponaria saponins, constitutes the licensed Leishmune® vaccine for prophylaxis of canine visceral leishmaniasis 
[3]. As a DNA vaccine, the NH36 induces a TH1 immune response [4,5], and  is prophylactic and 
immunotherapeutic against mice [4,5] and canine visceral leishmaniasis [6]. Visceral and tegumentar leishmaniaisis 
are both human diseases of increasing incidences, very toxic chemotherapy and overlapping epidemiological 
distribution. A potent vaccine against visceral leishmaniasis, which is the most severe disease, could potentially 
protect against tegumentar disease. In previous work, we tested in mice the immune response and protection induced 
by the purified FML antigen, the recombinant NH36 (rNH36), both in combination with saponin, and by the NH36 
DNA vaccine (VR1012-NH36), against the Brazilian agent of visceral leishmaniasis (L. (L.) chagasi) and against 
the Mexican agent of tegumentar leishmaniasis (L. (L.) mexicana) [4]. Animals challenged with L. (L.) chagasi
showed enhanced IgG responses induced by the three vaccines being the FMLSAP the most potent formulation 
followed by NH36SAP and VR1012NH36, while mice challenged with L. (L.) mexicana, showed a global non-
specific enhancement of IgG antibodies [4]. The intradermal reaction to both parasite antigens was enhanced in mice 
immunised with either rNH36 or FML while mice immunised with VR1012-NH36 reacted only against L. (L.) 
donovani. After FML and NH36 vaccination, reduction of parasitic load was achieved in L.(L.) chagasi infected 
mice (79%), while FML vaccination induced also 27% of reduction in L.(L.) mexicana experiment. The highest 
protection developed against both infections was seen in mice immunised with the VR1012-NH36 DNA vaccine 
which showed 88% of protection against L.(L.) chagasi and 47% protection against L.(L.) mexicana infections. 
FACS analysis disclosed normal total CD4+ and CD8+ T cell populations, with a 2-3 fold increase in IFNȖ-
producing CD4+ T cells, characteristic of the induction of a TH1 type immune response [4]. Our results showed a 
strong and specific immunoprotection of the NH36-DNA vaccine against visceral leishmaniasis and a milder but 
also protective effect against tegumentar leishmaniasis by L.(L.) mexicana pointing out its potential use in a bivalent 
vaccine tool for the control of both endemies [4]. In the present work, we analyzed the potential of the NH36 DNA 
and the FML-saponin vaccines against mice tegumentar visceral leishmaniasis provoked by the Brazilian agent of 
the disease, Leishmania (L.) amazonensis. We here evaluate the protection induced by three sc doses of FML 
(150µg) + saponin (100µg) with a week interval, or by two im doses of VR1012 empty plasmid (100µg) or 
VR1012NH36 (100µg) vaccine, with two weeks interval, against the footpad L.(L.) amazonensis infection with 106
promastigotes obtained after in vitro culture in NNN media, of amastigotes isolated hamsters lesions. Saline treated 
mice were used as controls. The anti-FML IgA, IgM, IgG, IgG1, IgG2a, IgG2b and IgG3 humoral responses was 
assayed by the FML-ELISA one week after complete vaccination and 33 weeks after infection. The cellular immune 
response was evaluated by the delayed type hypersensitivity (DTH) response against the lysate of 107 stationary 
phase promastigote of L. (L.) amazonesis, measured in the right hind footpads and subtracted from the values of 
saline treated left hind footpads, at 24h and 48h after injection, one week after vaccination and on week 33 after 
infection. Protection was assayed by the reduction of footpad swelling and lesions and survival analysis. Statistical 
analysis of differences was performed by ANOVA analysis simple factorial test and by one way ANOVA- Tukey´s 
honestly significant difference method (SPSS for windows). At week 33 after infection the survival animals were 
euthanized. 
No significant increase of anti-FML types or subtypes of antibodies were detected after complete vaccination. On 
week 33 after infection on the other hand, the anti-FML IGG, IgG1 and IgG2a antibodies were significantly 
increased over the saline controls only in the FML saponin vaccinated animals, confirming previous findings about 
the induction of humoral response by this vaccine [3,4]. The DNA vaccine and the naked plasmid did not enhance 
any antibody secretion (not shown). The DTH response against L.(L.) amazonesis lysate was increased by both 
vaccines over the saline controls before infection. On week 33 however, as expected for tegumentar leishmaniasis, 
the saline treated controls showed also specific DTH reaction (not shown).  
Regarding the reduction of parasite lesions, at week 26 after infection, significant differences were found in the 
footpad swelling (ANOVA; p=0.004). Considering the average of each group, the DNA vaccine induced 80.4%, the 
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empty plasmid 26.5% and the FML vaccine, 49% of reduction (p<0.05) indicating antigen-specific protection. 
Considering the individual evolution of mice (Figure 1), also the highest protection was determined by the DNA 
vaccine. Indeed, the increase in footpad sizes was detected in 5 of 7 mice treated with saline, 3 treated with empty 
plasmid, in 1 treated with the FML and in only 2 treated with the NH36 DNA vaccine (Figure 1). Noteworthy, the 
increase in the NH36 DNA treated mice started on week 26 while in other groups, between weeks 12-14 (Figure 1).  
At week 31 the saline treated animals showed higher footpad swelling than both (p<0.05), the VR1012 plasmid and 
the VR1012-NH36 group.  
At the end of the assay, on week 33, survival was 90% for the DNA vaccine group and 70% for the empty 
plasmid, FMLSAP and saline treated animals (Figure 2). Of note, while deaths begun at week 12 in other groups, 
the only obit in the DNA vaccinated animals occurred at week 33. Our results point out that the NH36 gene of L. 
donovani, as a DNA vaccine, followed by the FMLSAP vaccine, induce significant cross-protective response 
against tegumentar leishmaniasis induced by L. (L.) mexicana [4] and by L.(L.) amazonensis, indicating its potential 
use as bivalent vaccines in the different endemic regions of America.  
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Figure 1 Evolution of footpad swelling in Balb/c mice (n=7 for each treatment) treated with saline, VR1012 
plasmid, FML-saponin or VR1012-NH36 DNA vaccine, after challenge with Leishmania (L.) amazonensis infective 
promastigotes. 
Figure 2. Mice survival after vaccination and infection with promastigotes of L.(L.) amazonensis
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